NCT04412616: ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

NCT04412616
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04412616

Comments are closed.

Up ↑